动物疫苗市场机会、成长要素、产业趋势分析及2026-2035年预测。

预计到 2025 年，全球动物疫苗市场价值将达到 142 亿美元，并有望以 6.6% 的复合年增长率成长，到 2035 年达到 270 亿美元。

由于全球牲畜和宠物数量的增加、对动物性蛋白质需求的增长、宠物饲养率的上升以及兽医保健支出的增加，该市场正在扩张。牲畜和伴侣动物感染疾病的传播，以及人们对通用感染疾病和集体爆发风险日益增长的担忧，正在推动疫苗的普及。世界各国政府和监管机构正在实施更严格的动物健康政策和疫苗接种计划，以保护公众健康并最大限度地减少畜牧业的经济损失。兽医技术的进步，包括疫苗配方和给药系统的改进，进一步巩固了市场。农民和宠物饲主对食品安全和疾病预防意识的提高，也持续推动了对有效动物免疫解决方案的需求，使疫苗成为全球动物健康管理的重要组成部分。

预计到2025年，畜牧业市场规模将达94亿美元。畜牧业涵盖牛、家禽、猪、水产养殖、绵羊和山羊，由于其在全球粮食生产中的重要经济地位，成为推动市场成长要素。该行业的疫苗接种能够预防感染疾病的爆发，避免对肉类、乳製品和鸡蛋生产造成严重影响。政府和私人部门对畜牧业免疫计画的大量投资正在推动疫苗需求成长，从而保障动物福利和经济稳定。有效的疫苗接种方案有助于养殖户有效率地管理疾病爆发，减少损失，并支持永续的畜牧业发展模式。

预计到2025年，病毒感染疾病领域将占据55.3%的市场份额，到2035年将达到152亿美元。病毒感染疾病仍然是牲畜和伴侣动物面临的主要问题，因为它可能造成巨大的经济和健康负担。传染性病毒疾病的高发生率推动了对标靶疫苗的需求，以预防大规模疫情的爆发。兽医专业人员越来越重视病毒疫苗，将其视为保护畜群、提高生产力和维护食品安全标准的重要手段。

预计到2025年，北美动物疫苗市占率将达到41.7%，并在2026年至2035年间以6.3%的复合年增长率成长。该地区的主导地位得益于先进的兽医基础设施、高额的动物保健支出以及大规模的畜牧养殖。强有力的疾病预防计画、庞大的动物存栏量以及政府主导的监测倡议进一步巩固了北美的地位。美国凭藉其高疫苗接种率、兽医专业知识以及领先的动物用药品公司在研发和分销网络方面的投入，为该地区的成长做出了重大贡献。

目录

第一章：调查方法和范围

第二章执行摘要

第三章业界考察

• 生态系分析
• 影响产业的因素
  • 促进因素
    • 通用感染疾病发生率增加
    • 畜牧业扩张及对粮食安全的担忧
    • 宠物数量的增加和动物医疗保健支出的增加。
    • 疫苗技术的进步
    • 动物疾病发生率增加
  • 产业潜在风险与挑战
    • 高昂的开发成本
    • 严格的监管要求
  • 市场机会
    • 新兴市场兽医保健基础设施的扩张
    • 预防性兽医学的广泛应用
• 成长潜力分析
• 监理情势（基于初步调查）
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
  • 亚太地区
• 科技与创新趋势
  • 目前技术
  • 新兴科技及其影响
• 临床试验和研发管线分析（基于初步调查）
• 专利分析（基于初步研究）
• 人工智慧对市场的影响
• 波特五力分析
• PESTEL 分析

第四章 竞争情势

• 介绍
• 企业市占率分析
  • 北美洲
  • 欧洲
  • 亚太地区
• 企业矩阵分析
• 主要市场公司的竞争分析
• 竞争定位矩阵
• 主要进展
  • 併购
  • 伙伴关係与合作
  • 新产品发布
  • 业务拓展计划

第五章 市场估算与预测：依动物种类划分，2022-2035年

• 家畜
  • 家禽
  • 牛
  • 猪
  • 水产养殖
  • 绵羊和山羊
• 伴侣动物
  • 狗
  • 猫
  • 马
  • 鸟类

第六章 市场估计与预测：疫苗类型，2022-2035年

• 减毒活病毒疫苗
• 结合疫苗
• 灭活疫苗
• DNA疫苗
• 重组疫苗
• 其他疫苗类型

第七章 市场估计与预测：依应用领域划分，2022-2035年

• 细菌感染疾病
• 病毒感染疾病
• 寄生虫感染疾病
• 霉菌感染疾病
• 其他用途

第八章 市场估计与预测：依给药途径划分，2022-2035年

• 注射疫苗
• 口服疫苗
• 浸泡/喷洒疫苗

第九章 市场估价与预测：依通路划分，2022-2035年

• 兽药
• 普通药房
• 电子商务

第十章 市场估价与预测：依地区划分，2022-2035年

• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国

第十一章：公司简介

• Boehringer Ingelheim International
• Brilliant Bio Pharma
• Bioveta
• Ceva Sante Animale
• Dechra Pharmaceuticals
• Elanco Animal Health
• Henry Schein Animal Health（Covetrus, Inc.）
• Hipra Animal Health Limited
• Indian Immunologicals
• Merck Animal Health
• Neogen Corporation
• Vetoquinol
• Virbac
• Zoetis

The Global Animal Vaccines Market was valued at USD 14.2 billion in 2025 and is estimated to grow at a CAGR of 6.6% to reach USD 27 billion by 2035.

The market is expanding due to rising global animal populations, growing demand for animal protein, increased adoption of pets, and higher veterinary care expenditure. The increasing prevalence of infectious diseases in livestock and companion animals, along with heightened concerns over zoonotic diseases and outbreak risks, has driven vaccine adoption. Governments and regulatory authorities worldwide are implementing stricter animal health policies and vaccination programs to safeguard public health and minimize economic losses in the livestock sector. Technological advancements in veterinary medicine, including improved vaccine formulations and delivery systems, further strengthen the market. Rising awareness of food security and disease prevention among farmers and pet owners has also created a sustained demand for effective animal immunization solutions, making vaccines a critical component of animal health management globally.

The livestock animals segment generated USD 9.4 billion in 2025. The livestock segment, encompassing cattle, poultry, swine, aquaculture, and sheep and goats, is a key driver due to its economic significance in global food production. Vaccination in this sector prevents outbreaks of infectious diseases that could severely impact meat, dairy, and egg production. High private and government investments in livestock immunization programs fuel the demand for vaccines, ensuring both animal welfare and economic stability. Effective vaccination protocols help farmers manage disease outbreaks efficiently, reducing losses and supporting sustainable livestock farming practices.

The viral infections segment accounted for 55.3% share in 2025 and is expected to reach USD 15.2 billion by 2035. Viral infections remain a major concern for both livestock and companion animals, as diseases can cause significant economic and health burdens. The high prevalence of contagious viral conditions drives demand for targeted vaccines that prevent widespread outbreaks. Animal health professionals increasingly rely on viral vaccines as essential tools to protect animal populations, enhance productivity, and maintain food safety standards.

North America Animal Vaccines Market held a 41.7% share in 2025 and is anticipated to grow at a 6.3% CAGR during 2026-2035. The region's leadership is driven by advanced veterinary healthcare infrastructure, high animal healthcare spending, and extensive livestock production. Strong disease prevention programs, a large animal population, and government-backed monitoring initiatives further strengthen North America's position. The U.S. contributes significantly to regional growth due to robust vaccination adoption, veterinary expertise, and investments by major animal health companies in research, development, and distribution networks.

Key players in the Global Animal Vaccines Market include Boehringer Ingelheim International, Zoetis, Vetoquinol, Indian Immunologicals, Hipra Animal Health Limited, Dechra Pharmaceuticals, Merck Animal Health, Ceva Sante Animale, Elanco Animal Health, Neogen Corporation, Virbac, Brilliant Bio Pharma, Bioveta, and Henry Schein Animal Health (Covetrus, Inc.). Companies in the Global Animal Vaccines Market focus on expanding their presence by investing heavily in research and development to create innovative and highly effective vaccines. Strategic collaborations with veterinary clinics, distributors, and government programs help extend their market reach. Businesses leverage advanced manufacturing technologies to improve vaccine efficacy, reduce costs, and enhance delivery systems. Targeting emerging markets with rising livestock production and pet ownership ensures sustained growth. Marketing initiatives emphasize disease prevention, animal welfare, and economic benefits, building trust among farmers and pet owners. Participation in international trade shows, certification programs, and partnerships with animal health associations also strengthens brand recognition and competitive positioning globally.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research approach
• 1.3 Quality commitments
  • 1.3.1 GMI AI policy and data integrity commitment
    • 1.3.1.1 Source consistency protocol
• 1.4 Research trail and confidence scoring
  • 1.4.1 Research trail components
  • 1.4.2 Scoring components
• 1.5 Data collection
  • 1.5.1 Partial list of primary sources
• 1.6 Data mining sources
  • 1.6.1 Paid sources
    • 1.6.1.1 Sources, by region
• 1.7 Base estimates and calculations
  • 1.7.1 Revenue share analysis
  • 1.7.2 Base year calculation
• 1.8 Forecast model
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Animal type trends
  • 2.2.3 Vaccine type trends
  • 2.2.4 Application trends
  • 2.2.5 Route of administration trends
  • 2.2.6 Distribution channel trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of zoonotic diseases
    • 3.2.1.2 Expanding livestock industry and food security concerns
    • 3.2.1.3 Increasing pet adoption and expenditure on animal health
    • 3.2.1.4 Advancements in vaccine technology
    • 3.2.1.5 Increasing outbreaks of animal diseases
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High development costs
    • 3.2.2.2 Stringent regulatory requirements
  • 3.2.3 Market opportunities
    • 3.2.3.1 Expansion of veterinary healthcare infrastructure in emerging markets
    • 3.2.3.2 Increasing adoption of preventive veterinary care
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape (Driven by Primary Research)
  • 3.4.1 North America
    • 3.4.1.1 U.S.
    • 3.4.1.2 Canada
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
• 3.5 Technology and innovation landscape
  • 3.5.1 Current technologies
  • 3.5.2 Emerging technologies and their impact
• 3.6 Clinical trial/pipeline analysis (Driven by Primary Research)
• 3.7 Patent analysis (Driven by Primary Research)
• 3.8 Impact of AI on the market
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 North America
  • 4.2.2 Europe
  • 4.2.3 Asia Pacific
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Animal Type, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Livestock animals
  • 5.2.1 Poultry
  • 5.2.2 Cattle
  • 5.2.3 Swine
  • 5.2.4 Aquaculture
  • 5.2.5 Sheep and goats
• 5.3 Companion animals
  • 5.3.1 Canine
  • 5.3.2 Feline
  • 5.3.3 Equine
  • 5.3.4 Avian

Chapter 6 Market Estimates and Forecast, By Vaccine Type, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Attenuated live vaccine
• 6.3 Conjugate vaccine
• 6.4 Inactivated vaccine
• 6.5 DNA vaccine
• 6.6 Recombinant vaccine
• 6.7 Other vaccine types

Chapter 7 Market Estimates and Forecast, By Application, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Bacterial infections
• 7.3 Viral infections
• 7.4 Parasitic infections
• 7.5 Fungal infections
• 7.6 Other applications

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Injection vaccines
• 8.3 Oral vaccines
• 8.4 Immersion/spray vaccines

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 Veterinary hospital pharmacies
• 9.3 Retail pharmacies
• 9.4 E-commerce

Chapter 10 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 Boehringer Ingelheim International
• 11.2 Brilliant Bio Pharma
• 11.3 Bioveta
• 11.4 Ceva Sante Animale
• 11.5 Dechra Pharmaceuticals
• 11.6 Elanco Animal Health
• 11.7 Henry Schein Animal Health (Covetrus, Inc.)
• 11.8 Hipra Animal Health Limited
• 11.9 Indian Immunologicals
• 11.10 Merck Animal Health
• 11.11 Neogen Corporation
• 11.12 Vetoquinol
• 11.13 Virbac
• 11.14 Zoetis